The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Highlights in brain metastasis research at ESMO 2026
Ariane Steindl, PhD, Medical University of Vienna, Vienna, Austria, discusses the highlights in brain metastasis research presented at ESMO 2026, noting the increased inclusion of these patients in lung and breast cancer trials, but emphasizing the need for more data on patients with active brain metastases. Dr Steindl highlights the promising results of the TUXEDO-3 (NCT05865990) trial, which demonstrated the efficacy of antibody-drug conjugates (ADCs) in patients with active brain metastasis from lung cancer, breast cancer, and leptomeningeal disease. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
